Artelo Doses First Patient in Phase 2 Glaucoma Trial, Results Expected Q4
ARTL is trading near its 52-week low of $0.705 (6.5% above the low) on light trading volume (0.1× avg).
Summary
Artelo has enrolled the first patient in the DREAM study, a Phase 2 trial testing its oral cannabinoid ART27.13 for glaucoma and ocular hypertension. The study is fully funded by Glaucoma UK and the HSC R&D Division, removing near-term financial burden from the company. Initial results are expected in Q4 2026, providing a near-term catalyst. This expands ART27.13's pipeline beyond cancer anorexia, where interim Phase 2 data showed a 6% weight gain at the highest dose. The trial addresses a large market—over 80 million glaucoma patients worldwide—with a novel mechanism targeting intraocular pressure without CNS side effects. Given Artelo's going concern warning and recent dilutive financing, positive data could significantly de-risk the asset and attract partnership interest.
At the time of this announcement, ARTL was trading at $0.75 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.5M. The 52-week trading range was $0.71 to $31.65. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.